A recent concept in brain tumor biology is that brain tumors arise from cancer stem cells (CSCs) that are CD133 positive (CD133 (+)).It has been reported that a small number of CD133 ...

The second was designed as a dual antigen T cell engager antibody, which uses the patient’s own immune T cells to eliminate the CD133+ glioblastoma. The third was developed as a CAR-T therapy.

The second is a dual antigen T cell engager antibody, which uses the patient's own immune T cells to eliminate the CD133+ glioblastoma. The third is the CAR-T therapy.

Results: We found that in recurrent glioblastoma the percentage of CD133+ cells was increased by 2 folds in average as compared with tumors at first diagnosis, though in some instances CD133 ...

Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme. Background: Cancer stem cells (CSC) are thought to represent the ...

Further, T cells treated with KROS 101 showed cytotoxicity against glioblastoma cell lines and glioma cancer cells, which study authors, Admasu, et. al., concluded KROS 101 demonstrated potent ...

The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

“Traditional NK cell engagers, or NKCEs, are antibody-like molecules that bring NK cells and cancer cells in close contact. This stimulates the immune cell to kill the cancer,” he said. “The engagers ...